

Special Issue

Novel Challenges and Advances in Neuro-Oncology

Message from the Guest Editors

Neuro-oncology has seen remarkable strides recently. New perioperative mapping techniques have deepened our brain understanding, while basic science advances shed light on tumour-brain dynamics, enabling personalized surgical resections. Intraoperative diagnostics now guide surgical teams in crafting patient-centred resection plans, balancing risks and benefits.

Rehabilitation is evolving too, with patient-specific brain stimulation programs enhancing motor and cognitive recovery, boosting quality of life, and speeding up adjuvant treatment when needed. Beyond surgery, adjuvant therapies have diversified, revolutionizing oncological and functional outcomes.

Yet, challenges persist. Targeted sampling and focused, low-side-effect treatments are still sought after, driven by recent progress. While disease control and cure may be distant for many neuro-oncological conditions, they remain ultimate goals, achievable through incremental steps.

We invite you to submit your work to this topic so we can contribute and summarize recent developments in the field and help to pave the way for future advances.

Guest Editors

Prof. Dr. Keyoumars Ashkan


King's College Hospital NHS Foundation Trust, London SE5 9RS, UK

Dr. José Pedro Lavrador

King's College Hospital NHS Foundation Trust, London SE5 9RS, UK

Deadline for manuscript submissions

30 September 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/259537

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).